ライフサイエンスコーパス: early-stage breast cancer

1 ACH]: Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer).

2 ed with doxorubicin plus cyclophosphamide in early stage breast cancer.

3 r arising in patients previously treated for early stage breast cancer.

4 cterize clinically relevant heterogeneity in early stage breast cancer.

5 ortality among women with previously treated early stage breast cancer.

6 e initial adjustment of women diagnosed with early stage breast cancer.

7 ncer recurrence in hormone receptor-positive early-stage breast cancer.

8 have proven benefit as adjuvant therapy for early-stage breast cancer.

9 otherapy in a population of older women with early-stage breast cancer.

10 to neoadjuvant chemotherapy in patients with early-stage breast cancer.

11 ction in women treated with chemotherapy for early-stage breast cancer.

12 2 years, standard deviation: 6.2 years) with early-stage breast cancer.

13 e response among patients with HER2-negative early-stage breast cancer.

14 identified women 67 to 94 years of age with early-stage breast cancer.

15 tes of recurrence and death in patients with early-stage breast cancer.

16 side effects than tamoxifen in patients with early-stage breast cancer.

17 t from adjuvant trastuzumab in patients with early-stage breast cancer.

18 ee and overall survival for older women with early-stage breast cancer.

19 irm the poorer prognosis of obese women with early-stage breast cancer.

20 abine in patients age 65 years or older with early-stage breast cancer.

21 eatment and experience higher mortality from early-stage breast cancer.

22 ith reduced overall survival in survivors of early-stage breast cancer.

23 mportant competing risk for older women with early-stage breast cancer.

24 vant treatment for postmenopausal women with early-stage breast cancer.

25 in postmenopausal hormone receptor-positive early-stage breast cancer.

26 ognosis and treatment benefit for women with early-stage breast cancer.

27 e benefit of adjuvant therapy for women with early-stage breast cancer.

28 ce with anastrozole therapy among women with early-stage breast cancer.

29 owledge of surgical therapy among women with early-stage breast cancer.

30 important adjuncts for counseling women with early-stage breast cancer.

31 adjustment after diagnosis and treatment for early-stage breast cancer.

32 of depressive symptoms in women treated for early-stage breast cancer.

33 estrogen receptor (ER) status in women with early-stage breast cancer.

34 epidermal growth factor receptor 2-positive early-stage breast cancer.

35 vant treatment for postmenopausal women with early-stage breast cancer.

36 omy are definitive treatments for women with early-stage breast cancer.

37 ausal women receiving adjuvant letrozole for early-stage breast cancer.

38 sk of fractures in postmenopausal women with early-stage breast cancer.

39 rvival in women who have been diagnosed with early-stage breast cancer.

40 ycles among women receiving chemotherapy for early-stage breast cancer.

41 event in a cohort of women with a history of early-stage breast cancer.

42 ase in the SLN and bone marrow of women with early-stage breast cancer.

43 e through February 2004 on the use of SNB in early-stage breast cancer.

44 CEGT does not prolong survival in women with early-stage breast cancer.

45 ta on the risk of cardiovascular death after early-stage breast cancer.

46 detected in BM aspirates from patients with early-stage breast cancer.

47 psilateral breast tumor recurrence (IBTR) in early-stage breast cancer.

48 y does not adversely affect the prognosis of early-stage breast cancer.

49 ealth consensus statement recommendation for early-stage breast cancer.

50 stases in previously untreated patients with early-stage breast cancer.

51 and Cdk2 are suitable therapeutic targets in early-stage breast cancer.

52 y and tangential radiation therapy (TRT) for early-stage breast cancer.

53 LE gain for young women with BRCA-associated early-stage breast cancer.

54 parison with doxorubicin-cyclophosphamide in early-stage breast cancer.

55 ease outcome in a large cohort of women with early-stage breast cancer.

56 fine the shape of the dose-response curve in early-stage breast cancer.

57 ppropriate supportive care for patients with early-stage breast cancer.

58 ot suggest underuse among elderly women with early-stage breast cancer.

59 elderly black and white women diagnosed with early-stage breast cancer.

60 ab in neoadjuvant treatment of HER2-positive early-stage breast cancer.

61 in the treatment of patients age >/= 65 with early-stage breast cancer.

62 tion of pathologic and molecular features in early-stage breast cancer.

63 mph nodes improves survival in patients with early-stage breast cancer.

64 prediction of clinical outcome in women with early-stage breast cancer.

65 sentinel node biopsy (SNB) for patients with early-stage breast cancer.

66 surgery (BCS) in the majority of women with early-stage breast cancer.

67 ith node-positive or high-risk node-negative early-stage breast cancer.

68 n CT decisions in patients with ER-positive, early-stage breast cancer.

69 and medical expenditures among patients with early-stage breast cancer.

70 vant chemotherapy regimens are available for early-stage breast cancer.

71 adjuvant trastuzumab use in older women with early-stage breast cancer.

72 O-1 expression and metastatic progression in early-stage breast cancer.

73 al growth factor receptor 2 (HER2) -positive early-stage breast cancer.

74 for women age >/= 70 years with ER-positive early-stage breast cancer.

75 ate-stage breast cancers as oppose to 13% in early-stage breast cancers.

76 r mortality by detecting small, nonpalpable, early-stage breast cancers.

77 o identify factors that predict diagnosis of early-stage breast cancers.

78 Three surgical options exist for early stage breast cancer: (1) breast conserving surgery

79 in a selection of patients with ER-positive, early-stage breast cancer, 70-GS use changed the physici

80 n of paclitaxel as adjuvant chemotherapy for early-stage breast cancer, 9 months after presentation o

81 treatment at six New York City hospitals for early-stage breast cancer about their care, knowledge, a

82 Among survivors of early stage breast cancer, adoption of a diet that was v

83 gical (NP) testing outcomes in patients with early-stage breast cancer after the initiation of endocr

84 oglobin A1C (HbA1C) among 3,003 survivors of early-stage breast cancer (age of diagnosis, 28 to 70 ye

85 Early-stage breast cancer, age, cardiovascular disease,

86 uperior to those of placebo among women with early-stage breast cancer, although it resulted in more

87 ages (+/- SE) measured from the diagnosis of early-stage breast cancer among the 94 study group patie

88 ivalent to mastectomy for most patients with early-stage breast cancer, an increasing number of patie

89 phosphamide, in patients with HER2-amplified early stage breast cancer and examined whether this regi

90 rstone of adjuvant therapy for patients with early stage breast cancer and oestrogen-receptor-positiv

91 agement for a sizable fraction of women with early-stage breast cancer and appears to offer clinicall

92 , phase 3 study, we enrolled 6693 women with early-stage breast cancer and determined their genomic r

93 evolutionised the treatment of HER2-positive early-stage breast cancer and is now standard of care in

94 itaxel is active against HER2 overexpressing early-stage breast cancer and may be feasible as part of

95 irradiation (WBI) for selected patients with early-stage breast cancer and permitted hypofractionated

96 aged 20 to 44 years who were diagnosed with early-stage breast cancer and received a CPM increased i

97 se of the widespread use of chemotherapy for early-stage breast cancer and the improved survival.

98 receiving specific chemotherapy regimens for early-stage breast cancer and to assess related changes

99 y in the underuse of adjuvant treatments for early-stage breast cancer and to identify associated fac

100 or older diagnosed with invasive unilateral early-stage breast cancer and treated with surgery from

101 ncluded AI-treated postmenopausal women with early-stage breast cancer and who had average joint pain

102 inion use was low (<10%) among patients with early-stage breast cancer, and high decision satisfactio

103 than tamoxifen by postmenopausal women with early-stage breast cancer, and results in fewer serious

104 breast cancer, adjuvant endocrine therapy in early-stage breast cancer, and salvage chemotherapy in a

105 tatus of the axillary nodes in patients with early-stage breast cancer, and SLN mapping is gaining wi

106 Individuals who receive chemotherapy for early-stage breast cancer are a select subgroup of patie

107 Some women with early-stage breast cancer are at higher risk of recurren

108 women treated for depression before primary early-stage breast cancer are at increased risk for rece

109 Depressive symptoms in women treated for early-stage breast cancer are not associated with object

110 Early-stage breast cancers are biologically heterogeneou

111 Women with early-stage breast cancers are expected to have excellen

112 g 746 postmenopausal patients diagnosed with early-stage breast cancer at 30 hospitals located throug

113 Optimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity

114 ng vaginal ring (7.5 mug/d) in patients with early-stage breast cancer (BC) receiving an AI.

115 30 years and older who underwent surgery for early-stage breast cancer between 1983 and 1995.

116 had completed systemic adjuvant therapy for early-stage breast cancer between 1988 and 1991 were sur

117 med of 1,490 women diagnosed and treated for early-stage breast cancer between 1991 and 2000.

118 Medicare records for patients diagnosed with early-stage breast cancer between 2001 and 2007, tumor m

119 MarketScan database who were diagnosed with early-stage breast cancer between 2003 and 2007.

120 s conducted among 98999 women diagnosed with early-stage breast cancer between April 1, 1998, and Mar

121 ndomly assigned 455 women with HER2-positive early-stage breast cancer between January 5, 2008, and M

122 For early-stage breast cancer, breast conservation surgery (

123 ssed receipt of definitive local therapy for early-stage breast cancer by race/ethnicity and age and

124 d cohort (n=5439), the Nottingham historical early stage breast cancer cohort (Nottingham-HES; n=1650

125 In this large early-stage breast cancer cohort, MN risk after radiatio

126 red thirty-nine women previously treated for early-stage breast cancer completed surveys that present

127 of 49-year-old women with HER2/neu-positive early-stage breast cancer: conventional chemotherapy wit

128 stantial increases in the number of cases of early-stage breast cancer detected, screening mammograph

129 le blood has potential as a novel method for early stage breast cancer detection, but there are still

130 Nearly 30% of women with early-stage breast cancer develop recurrent disease attr

131 women who had received standard therapy for early-stage breast cancer diagnosed between September 19

132 nt guidelines for the systemic management of early-stage breast cancer differ when applied to stage T

133 east cancer outcomes in women diagnosed with early-stage breast cancer differs on the basis of tumor

134 Approximately 20% of early-stage breast cancers display amplification or over

135 Worldwide, many patients with HER2-positive early stage breast cancer do not receive trastuzumab-the

136 s from 1976 through 2008 in the incidence of early-stage breast cancer (ductal carcinoma in situ and

137 Adult women diagnosed with early-stage breast cancer during 1990-2008 (n = 3,965) w

138 conservation therapy (BCT) for patients with early-stage breast cancer during a period of treatment e

139 e quality of systemic therapy for women with early-stage breast cancer (EBC).

140 rogen receptor-positive, lymph node-negative early-stage breast cancer (EBC).

141 premenopausal women undergoing treatment for early-stage breast cancer (EBC).

142 e feasibility and cardiac safety of T-DM1 in early-stage breast cancer (EBC).

143 CAM use was high among patients with early-stage breast cancer enrolled in a multisite prospe

144 Of the 374 new patients with early-stage breast cancer enrolled onto the RCT, only a

145 actice patterns in adjuvant chemotherapy for early-stage breast cancer (ESBC) and to define the incid

146 in selecting adjuvant therapy for women with early-stage breast cancer for endorsement.

147 ssemble a retrospective cohort of women with early-stage breast cancer from 2007 to 2010 who underwen

148 opausal women with hormone receptor-positive early-stage breast cancer from the ABCSG 8 and TransATAC

149 ng a prospective design, 6,211 patients with early-stage breast cancer from two large population-base

150 reventing recurrence and death in women with early-stage breast cancer, further efforts are necessary

151 study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically im

152 Although the prognosis for patients with early-stage breast cancer has improved, the therapeutic

153 erence to tamoxifen therapy among women with early-stage breast cancer has revealed adherence estimat

154 ical approach of the axilla in patients with early-stage breast cancer has witnessed considerable evo

155 curately staging the axilla in patients with early-stage breast cancer have become progressively less

156 Adjuvant treatments for early-stage breast cancer have been shown to improve hea

157 Minority women with early-stage breast cancer have double the risk of white

158 juvant anthracycline therapy in survivors of early-stage breast cancer have had limited study.

159 Outcomes for early-stage breast cancer have improved.

160 Many patients with early-stage breast cancer have treatment options and app

161 In early-stage breast cancer, high TS expression is associa

162 uvant radiation therapy in the management of early stage breast cancer, Hodgkin's disease, and to a l

163 native to whole-breast irradiation (WBI) for early-stage breast cancer; however, current national tre

164 onserving surgery increased among women with early-stage breast cancer in 14 US commercial health car

165 men, aged 20 years and older, diagnosed with early-stage breast cancer in 1987 to 1991, 1995, and 200

166 Treatment of early-stage breast cancer in HMOs often differs from loc

167 erformed among 1,514 patients diagnosed with early-stage breast cancer in Massachusetts and 1,061 pat

168 d 1,081 women (response, 70%) diagnosed with early-stage breast cancer in Massachusetts or Minnesota

169 priate care, the appropriateness of care for early-stage breast cancer in the USA declined from 1990

170 Management of early-stage breast cancer in young women with mutations

171 s performed of the records of 207 women with early-stage breast cancer (including five women with bil

172 ration of normal ductal epithelial cells and early-stage breast cancer invasion and stemness.

173 In patients with early-stage breast cancer, irradiation of the regional n

174 urance payer status on surgical treatment of early stage breast cancer is unclear.

175 ence to aromatase inhibitor (AI) therapy for early-stage breast cancer is limited by AI-associated mu

176 velopment of breast-conserving treatment for early-stage breast cancer is one of the most important s

177 n after surgery on survival among women with early-stage breast cancer is unknown.

178 f adjuvant radiation therapy, especially for early-stage breast cancer mandates long-term follow-up t

179 CT) is an accepted modality for treatment of early-stage breast cancer, many women continue to underg

180 erly black versus white women diagnosed with early-stage breast cancer; matching by tumor characteris

181 etiology of sporadic breast cancer, and that early-stage breast cancer may be intrinsically susceptib

182 A substantial proportion of women with early-stage breast cancer may be suboptimally adherent t

183 n other patients, suggesting that women with early-stage breast cancer may benefit from surgeons' eff

184 Evaluation of HSP90 expression in early-stage breast cancer may identify a subset of patie

185 Women diagnosed with early-stage breast cancer might improve overall prognosi

186 formance status of 1 or less; HER2-amplified early stage breast cancer; operable, histologically conf

187 ng on whole blood could discriminate between early stage breast cancer patients and healthy controls.

188 y-based miRNA profiling on whole blood of 48 early stage breast cancer patients at diagnosis along wi

189 e differentially expressed in whole blood of early stage breast cancer patients compared to healthy c

190 -qPCR) validation in a separate cohort of 24 early stage breast cancer patients from a breast cancer

191 Providing G-CSF to the neediest 50% of early-stage breast cancer patients (as defined by first-

192 he new standard of care for nodal staging in early-stage breast cancer patients and contraindications

193 ted genetic markers in BM aspirate plasma of early-stage breast cancer patients and provides a unique

194 etween oncologist adoption of paclitaxel for early-stage breast cancer patients and variables represe

195 Early-stage breast cancer patients completing medical tr

196 Early-stage breast cancer patients diagnosed from 1996 t

197 Non-recommended testing for early-stage breast cancer patients has decreased over ti

198 e (T) that would allow the most needy 50% of early-stage breast cancer patients to receive G-CSF afte

199 Observed rates of stroke in 820 eligible early-stage breast cancer patients treated at the Univer

200 er lumpectomy was prospectively evaluated in early-stage breast cancer patients treated with breast-c

201 Utilities (measures of preference) of 97 early-stage breast cancer patients treated with conserva

202 ased physical activity (PA) intervention for early-stage breast cancer patients was evaluated in a ra

203 olled 24 predominantly white, well-educated, early-stage breast cancer patients who were facing local

204 ompared with surveillance alone, 30-year-old early-stage breast cancer patients with BRCA mutations g

205 Local-regional recurrences are rare in early-stage breast cancer patients with H&E-negative SLN

206 mary breast tumor gene expression from 1,378 early-stage breast cancer patients with long-term clinic

207 In early-stage breast cancer patients, a 10-week CBSM inter

208 s a potential marker of improved survival in early-stage breast cancer patients, independent of the s

209 Participants included 5569 early-stage breast cancer patients, treated with breast-

210 te occult disease in SLNs and bone marrow of early-stage breast cancer patients.

211 ic aspects of psychological well-being among early-stage breast cancer patients.

212 d having adopted paclitaxel for 37% of their early-stage breast cancer patients.

213 on in breast tumors derived from a cohort of early-stage breast cancer patients.

214 How women with early-stage breast cancer perceive the risks and benefit

215 d who had undergone surgery for ER-positive, early-stage breast cancer, physicians were asked whether

216 ate the MammaPrint assay in 6,693 women with early-stage breast cancer provided a signal.

217 d and 21.2% with hypofractionation-permitted early-stage breast cancer received hypofractionated WBI

218 mental attitude toward cancer in women with early-stage breast cancer receiving adjuvant chemotherap

219 Women with early-stage breast cancer receiving an AI who had a wors

220 blood counts were performed in 20 women with early-stage breast cancer receiving four courses of cycl

221 nal expression and benefit finding regarding early-stage breast cancer reduced medical visits for can

222 most effective adjuvant therapy regimen for early-stage breast cancer regardless of hormone receptor

223 herapy with radiation (RT) for patients with early-stage breast cancer remains uncertain.

224 Adjuvant RT in early-stage breast cancer significantly reduces in-breas

225 All patients had early-stage breast cancer (stages 0-II).

226 atients with trastuzumab-naive HER2-positive early-stage breast cancer, started at any time after dia

227 equent CBC occurrence among older women with early-stage breast cancer, suggesting that preoperative

228 CS is an appropriate method of treatment for early stage breast cancer, surgeons in the United States

229 -3/CA 27.29 and associated Medicare costs in early-stage breast cancer survivors.

230 nd that a substantial fraction of women with early-stage breast cancer terminated their chemotherapy

231 7 women between the ages of 48 and 79 y with early-stage breast cancer tested the hypothesis that die

232 ed with a doubling in the number of cases of early-stage breast cancer that are detected each year, f

233 In early-stage breast cancer, the primary treatment option

234 nthracycline-based adjuvant chemotherapy for early-stage breast cancer, the use of scalp cooling vs n

235 recurrence and death among young women with early-stage breast cancer, they have not adequately addr

236 stasis) who had had local tumour excision of early stage breast cancer to receive 50 Gy radiotherapy

237 doxorubicin (A) and cyclophosphamide (C) in early-stage breast cancer to determine if administration

238 domly assigned 3222 women with HER2-positive early-stage breast cancer to receive doxorubicin and cyc

239 5351 patients with operable, node-positive, early-stage breast cancer to receive four cycles of doxo

240 rial randomized 455 women with HER2-positive early-stage breast cancer to trastuzumab, lapatinib, or

241 rial randomized 455 women with HER2-positive early-stage breast cancer to trastuzumab, lapatinib, or

242 A retrospective review of 55 women with early-stage breast cancer treated from 1990 to 1995 was

243 onable management for selected patients with early-stage breast cancer treated with breast-conserving

244 Among women with early-stage breast cancer treated with lumpectomy and ra

245 n 2013, we classified patients with incident early-stage breast cancer treated with lumpectomy and WB

246 Among the 1224947 women with early-stage breast cancer treated with surgery, the prop

247 is procedure to a microarray data set of 286 early-stage breast cancers treated only with surgery and

248 Medical records from 2,327 women with early-stage breast cancer, treated at the M.D. Anderson

249 epidermal growth factor receptor 2-positive, early-stage breast cancer (Tykerb Evaluation After Chemo

250 ndomized clinical trial of 324 patients with early-stage breast cancer undergoing chemotherapy (cyclo

251 es, nearly half of young women with invasive early-stage breast cancer underwent a CPM from 2010 to 2

252 oral trends in performance of mastectomy for early-stage breast cancer using multivariable logistic r

253 dy of women receiving adjuvant treatment for early-stage breast cancer was conducted.

254 Early-stage breast cancer was defined as having a tumor

255 ath in black versus white men diagnosed with early-stage breast cancer was largely confined to those

256 cohort of 480 patients with newly diagnosed early-stage breast cancer was recruited from a Massachus

257 ll beta-chain repertoire in 16 patients with early-stage breast cancer, we show that the clonal struc

258 Most older women with early-stage breast cancer were adherent to short-term or

259 zed trial in which postmenopausal women with early-stage breast cancer were assigned to receive anast

260 ery and radiation therapy (> or = 60 Gy) for early-stage breast cancer were categorized by FH.

261 578 women with early-stage breast cancer were enrolled in a prospective

262 ients who became pregnant after diagnosis of early-stage breast cancer were identified in institution

263 January 1993 and January 2000, 174 cases of early-stage breast cancer were managed with lumpectomy f

264 average, 2 years since primary treatment for early-stage breast cancer were randomly assigned to eith

265 cal trial in which postmenopausal women with early-stage breast cancer were randomly assigned to rece

266 One hundred sixty women with early-stage breast cancer were recruited from three trea

267 en (n = 288) undergoing adjuvant therapy for early-stage breast cancer were recruited from two outpat

268 he rates of LR and RR in young patients with early-stage breast cancer were relatively low and varied

269 inically annotated, microarray data from 784 early-stage breast cancers were identified, and prospect

270 h in a contemporary population of women with early-stage breast cancer while accounting for competing

271 change in 3088 women previously treated for early stage breast cancer who were 18 to 70 years old at

272 is superior to capecitabine in patients with early-stage breast cancer who are 65 years of age or old

273 Patients with early-stage breast cancer who are at substantial risk fo

274 marker that may help identify patients with early-stage breast cancer who could benefit from more ag

275 aged 18 years or older with newly diagnosed, early-stage breast cancer who had a definite indication

276 All 723 women with early-stage breast cancer who had a definitive surgical

277 Overweight or obese women with clinically early-stage breast cancer who had been assigned to under

278 Among women with newly diagnosed early-stage breast cancer who had been treated with stan

279 atients treated with breast conservation for early-stage breast cancer who subsequently underwent car

280 Proportion of women with early-stage breast cancer who underwent mastectomy.

281 Data from 1,021 nonpregnant women with early-stage breast cancer who underwent SLN mapping and

282 Among women with early-stage breast cancer who were at high clinical risk

283 Thirty-four young premenopausal women with early-stage breast cancer who were exposed to chemothera

284 We randomly assigned 303 women with early-stage breast cancer who were receiving adjuvant ch

285 In a follow-up study of 200 women with early-stage breast cancer who were treated with adjuvant

286 In this population of patients with early-stage breast cancer who were treated with adjuvant

287 ve to routine staging ALND for patients with early-stage breast cancer with clinically negative axill

288 f the treatment costs for elderly women with early-stage breast cancer, with emphasis on costs of mod

289 to include patients with large but operable early-stage breast cancer, with the possibility in some

290 Younger women (age < 51 years, N = 252) with early-stage breast cancer within 2 months of having comp

291 d acceptably accurate method for identifying early-stage breast cancer without involvement of the axi

292 ients with estrogen receptor (ER) -positive, early-stage breast cancer without overt lymph node metas

293 onducted to test whether older patients with early-stage breast cancer would have equivalent relapse-